Search by Name - Presenter / Author

Oslo University Hospital
Radiology and Nuclear Medicine
PhD-student in Neurology.
no photo
Heinrich Heine University
Institute of Anatomy ll
no photo
German University in Cairo
Pharmacology, Toxicology and Clinical Pharmacy
Autonomous University of Barcelona
Department of Medicine
Carla Abdelnour is a neurologist interested in studying dementia with Lewy bodies and finding therapeutic solutions for patients with dementia. She has experience in the management of clinical trials for Alzheimer´s disease and other neurodegenerative dementias, as well as social robotics projects to analyze human-robot interaction aiming to develop new care strategies for elderly patients with cognitive impairment.
University college London
Queen Square Brain Bank
I am a neurology trainee, based in London. I am currently undertaking my PhD, investigating the neuropathology of posterior cortical atrophy (PCA), at the Queen Square Brain Bank, University College London. PCA is a variant of Alzheimer’s disease (AD) which presents with visual and spatial problems rather than the memory problems seen in typical Alzheimer’s disease (TAD). The pathological proteins in PCA and TAD are the same: Aβ plaques and tau neurofibrillary tangles (NFTs). The question therefore is how the same underlying pathology causes such dramatically different clinical presentations and whether these two variants of AD start in different “selectively vulnerable” parts of the brain, or indeed have differing patterns of cortical spread and severity. There is an accumulating wealth of evidence towards distinct subtypes of AD based mainly on neuropathological and imaging studies although the potential biological mechanisms driving this heterogeneity remain unanswered. My aim is to carry out a comprehensive neuropathological characterisation of PCA cases including regional Aβ and NFT quantification, investigation of neuroinflammatory markers and proteomic studies.
University of Florida
Department of Neuroscience
Professor Abisambra trained at the University of South Florida, where he obtained his PhD while working on LDL receptor in Huntington Potter's Lab. He consequently focused on investigating the impact of chaperone proteins on tau biology as a postdoc in Chad Dickey's Lab. In 2013, he opened his lab as an Assistant Prof. in the Sanders-Brown Center on Aging at the University of Kentucky, where he focused on the impact of tau on ER stress and translation, in models of AD, Down syndrome, and TBI. He relocated in 2018 to the University of Florida as an Associate Professor, where he continues to focus his research program on tau and translation. Work from his lab, which is supported by federal and non-profit sources, has brought us closer to understanding the mechanisms by which tau impairs protein synthesis leading to maladaptive responses and cellular dysfunction in AD, FTD, and TBI. He is also an Assistant Dean of Diversity and Health Equity in the UF College of Medicine, where he assists graduate students in the Biomedical Sciences Program. But he is best known for single-parenting 4 kids under 7yo, 3 days a week, while his wife works as a nurse in Labor and Delivery at SHANDS hospital.
no photo
Neurosciences and Immuno-inflammation therapeutic area
no photo
German University in Cairo
Pharmacology, Toxicology and Clinical Pharmacy
no photo
Gothenburg University
Neuroscience and physiology
Abyad Medical Center
Dr Abyad has been involved with postgraduate medical education and professional teaching programs as a Team Leader for the CME/CPD (2006–2007), combining his public health and management expertise with his medical knowledge. Dr Abyad served as a Coordinator for the AinWaZein Geriatric Program where he created a comprehensive health care program for the elderly. He frequently serves as a consultant and advisor to numerous organisations including World health Organisation, Hamad Medical Corporation in Qatar, and University of Amman in Jordan, with his expertise in Aging, Family Medicine, and Development of services. Dr Abyad has published an extensive list of articles and book chapters about ageing, primary health care, public health care systems. He acts as peer reviewer for many organisations and is an international editorial board member of International Journal of Medicine, Journal of the Association of Health Care Professionals, Geriatrics Today, and World CME.
Eisai EU Limited
Clinical Pharmacology & Translational Medicine
Pharmacist by training, and with previous work experience in diverse aspects of the Pharmacy practice –including Community, Clinical and Production Pharmacy– Pau focused his professional career path in the field of Clinical Pharmacology (CP) and PK/PD Modelling & Simulation since 2006. Pau Aceves holds a Master’s Degree in PK/PD Modelling & Simulation from the University of Manchester in the UK. His MSc project was on an "Exploratory Quantitaitve Systems Pharmacology Model (QSP) of the Squalene Synthase Inhibitor Lapaquistat Acetate". Pau has a total of 15 years of QCP experience in the design, analysis and reporting of clinical studies in a wide range of therapeutic areas across all phases of drug development. Currently, at Eisai, he is focused in the area of Neurology and more specifically Alzheimer's Disease. In addition to having worked on CP-type studies (i.e. food effect, bioavailability, DDIs), Pau also has a wide range of experience in other modalities, including: First-in-Human (SAD/MAD), Proof-of-Mechanism (PoM), Proof-of-Concept (PoC), Positron Emission Tomography (PET), and complex combination (or umbrella-type) studies; as well as experience interacting with regulatory agencies (FDA, EMEA) at various stages of drug development. Pau always enjoys devising innovative strategies to streamline and maximize the value of clinical development programmes by combining efficient clinical strategies with fit-for-purpose PK/PD analysis methodologies (e.g. Population PK/PD, Physiologically Based Pharmacokinetic modelling, and Quantitative Systems Pharmacology approaches).
no photo
Rutgers, The State University of New Jersey
RWJMS Dept of Neurology
Dr. Adams completed his B.S. in Biochemistry in the US at the University of North Texas, and his Ph.D. at the University of Central Florida. His research focuses on molecular causes of neurodegeneration.
no photo
Osun State University Nigeria
Adebisi, Benjamin Temidayo ORCID iD: http://.org/0000-0001-8725-2048 Department of Anatomy, Osun State University, Osogbo +2348137681768. EDUCATION M.Sc. Anatomy September, 2012 Department of Anatomy and Cell Biology, Obafemi Awolowo University, Ile –Ife Thesis Title: Neuroprotective effects of Ethanolic extract of ginger (Zingiber officinale) in Monosodium glutamate-induced neurotoxicity of the Hippocampus and Cerebellum of Malnourished Wistar rats B.Sc. Human Anatomy May, 2006 Department of Anatomy, University of Ilorin, Ilorin TEACHING AND ADVISORY Anatomy Lecturer November, 2015- present Department of Anatomy, Osun State University, Osogbo, Nigeria • Taught Neuroanatomy, Gross Anatomy and Histology to students in Anatomy and Physiology • Planned lessons and assignments, led discussion section, graded papers and exam • Organized and led group discussions on social and academic issue Adjunct Assistant Lecturer October, 2014- April, 2015 Department of community Health, Lead City University, Ibadan, Nigeria • Planned and taught Introductory Anatomy and Physiology to first year students of Community Health Extension Workers department • Taught in part with an innovative, interdisciplinary team teaching- program design • Taught basis of Cellular and General Pathology to Environmental Health students   Demonstrator and Teaching assistant February, 2009- December, 2012 Obafemi Awolowo University, Ile- Ife, Nigeria • Led group discussion for second and third year medical students on academic topics • Dissected cadavers and instructed second and third year medical students in practical section in Gross Anatomy. • Integrated Multimedia approaches using film and instructional technology to teach anatomy RESEARCH EXPERIENCE Michael J. Fox Foundation September, 2016 - December. 2019 • Designed a proposal Title Stimulating the action of Rab1 in reversing accumulation of alpha-synuclein in Parkinson disease • Designed a proposal titled Alpha-Synuclein Oligomerization”: The Headway towards understanding Parkinson Disease and achieving Targeted therapy • Designed a proposal titled Mitochondria toxicity: A key towards understanding Alpha-synuclein aggregation and targeted therapy in Parkinson Disease. • Designed a proposal titled Modulatory Role of Dopamine and Vesicular Monoamine Transporter-2 (VMAT2) by Alpha-Synuclein: Target Pharmacological Therapeutic “Hope” for Parkinson’s Disease” • Designed a proposal titled Stimulating beta glucocerebrosidase (GCase) activities prevent alpha-synuclein aggregation in Parkinson’s disease. International Parkinson and Movement Disorder Society May, 2021 • Development of Curriculum Tracks for Advanced Guided Learning for Neurologists and Health Care Providers in the Movement Disorders Society MDS focusing on “Parkinson’s Disease: Role of Alpha-Synuclein in Parkinson disease”  THE INFORMATION TECHNOLOGY AND MY PRACTICAL APPLICATION OF MY RESEARCH The Information Technology has been an effective tool for me, in disseminating information and had improved the access to research materials and tools and also exhibition of personal researches and work to the International community. A reasonable amount of my time has been devoted in research and exploring my findings to several international community on the social media, including Neuroscience, MSA Coalition Group, The Michael J. Fox Foundation For Parkinson’s Research, MDS Young Members Group, among others. On the various platforms, are patients, caregivers, medical doctors and several researchers of several neurodegenerative diseases like Parkinson’s, Multiple System Atrophy and Amyotrophic Lateral Sclerosis. I have also been able to answer several questions relating to the biology of the etiopathogenesis of these debilitating diseases by making video lectures, writing monographs and related articles in Neuroscience. My researches have elucidated the role of Neuroscientists in unravelling and procuring therapeutic approaches for several diseases involving neurodegeneration and aging. These have given a practical application of my researches and what I think the best ways of mitigating the progression of these diseases. On the recent pandemic of COVID-19, I had made several videos explaining the Biological Mechanism of Corona Virus proliferation and the role the SARS-CoV-2, the virus that causes Covid19 play in Respiratory Insufficiency.   RESEARCH SUPERVISION August, 2016 – October, 2018 Supervised and led researches into: a) The cytotoxic effects of Haloperidol and possible protective effects of ethanolic extract of ginger (Zingiber officinale) on the testis of Adult Abino rats. b) The study of protein malnutrition on the histology of testes of wistar rats c) Effect of melatonin on testes of adult wistar rats treated with Monosodium-Glutamate d) Histological effects of antipsychotics on the testes of adult wistar rats e) Comparative study of the Neuroprotective properties of Riboflavin and Ascorbic acid in Monosodium Glutamate-induced neurotoxicity of the prefrontal cortex of Male wistar rats. f) Evaluation of the protective effects of ethanolic extract of Garlic (Allium sativum) on lead-induced cardiomyopathy of pubertal male wistar rats. g) The Hepatotoxic Effects of varying doses of Tramadol on Adult Male Wistar Rats h) Toxicological effects of varying doses of Tramadol on Stomach Histoarchitecture and gastric mucosa of Adult male rats. i) Neurotoxic effects of varying doses of Tramadol on the Cerebral cortex of Adult Male wistar rats. j) The Cytotoxic Effects of varying doses of Tramadol on the testes of Adult male wistar rats. k) Sexual Dimorphism in relation to Body Mass Index, Biacromial Stature Index and Body Parameters among students of Osun State University. (College of Health Sciences).   PUBLICATIONS 1. Adebisi Benjamin Temidayo, Adeleke Monsuru Adebayo, Olabiyi Omobolanle Fatima (2017): Stimulating the action of Rab-1 in reversing accumulation of alpha-synuclein in Parkinson Disease. The Brain Prize Meeting, 2017. 2. Modulatory role of dopamine and vesicular monoamine transporter-2 (VMAT2) by Alpha-synuclein: Target pharmacological therapeutic “Hope” for Parkinson’s disease. The Brain Prize Meeting, 2018. 3. Adebisi Benjamin (2018): Stimulating Beta- Glucocerebrosidase (GCASE) activities prevent Alpha- Synuclein Aggregation in Parkinson’s Disease. (Abstract). 4. Adebisi Benjamin Temidayo (2018): Glucocerebrosidase pathway as a therapeutic target for Neuroprotection in Parkinson Disease. (Abstract) Molecular and Cellular Cognition Society, 17th Annual Symposium, 2018. 5. Adebisi Benjamin Temidayo (2018): 1- Methyl-4-phenyl-1,2,3,6-Tetrahydroxyl Pyridine, MPTP- Induced Oxidative stress in the Mitochondria: The Role in Alpha Synuclein aggregation and Etiopathogenesis of Parkinson’s Disease. (Abstract) Molecular and Cellular Cognition Society, 17th Annual Symposium, 2018. 6. Adebisi Benjamin Temidayo (2018): Neuroprotective effects of Ethanolic extract of ginger (Zingiber officinale) in Monosodium glutamate-induced neurotoxicity of the Hippocampus and Cerebellum of Malnourished Wistar rats. . (Abstract) Molecular and Cellular Cognition Society, 17th Annual Symposium, 2018. 7. Adebisi Benjamin Temidayo (2019): Understanding the Structural conformation and Oligomerization of Alpha Synuclein gives an Insight in the pathology of the Progression of Parkinson’s Disease. (Abstract) imprs NeuroCom Summer School, 2019. 8. Abayomi T.A., Tokubo. O.S., Adebisi, B.T, Fadare, M.U., Gbadamosi, T.I., Akinwale, J.O., Sawyer, E.A. and Arogundae T.T. Neurobehavioural Assessment of the impact of Vitamins C and E following acute exposure to sodium azide-induced neurotoxicity. (2019). Journal of Enviromental Toxicity and Public Health. Volume 4: Pages 15-20. 9. Adebisi B. T., Famoye, D., Tiamiyu, M and Oyenike, M.A. (2019). Cardiotoxic effects of Haloperidol and cardioprotective effects of Ginger extract (Zingiber officinale) in adult male Albino rats. 10. B. Adebisi, M. Adeleke. Enhansing the Proteasomal Degradation of Alpha Synuclein: “The Hallmark’to attenuating the progression of Parkinson’s disease (Abstract). Mov Disord.2019: 34 (Suppl2). proteasomal-degradation-of alpha-synuclein-the hallmark-to-attenuating-the progression-of-parkinsons-disease/. accessed September 20,2019. 11. B. Adebisi. Proteasomal degradation of alpha synuclein by induction of heat shock proteins in Parkinson’s disease. Parkinsonism & Related Disorders Volume 79, Supplement, October 2020, Page 31. 12. Adebisi Benjamin. Mitochondrial Dysfunction: A Primary Event in Glutamate Neurotoxicity. 15th International Conference on Alzheimer’s and Parkinson’s Disease: Mechanisms, Clinical Strategies and Promising Treatments of Neurodegenerative Diseases. March 9-14, 2021. 13. Adebisi Benjamin Temidayo (2021): Cerebrospinal fluid cell count, as an indicator for inflammation and Neurological Condition. (Abstract). The Brain Prize Meeting: Neurodevelopmental Disorders. Mechanism and Pathways to Treatment. 1- 4 March, 2021. 14. B. Adebisi (2021): The Cytotoxic effects of Haloperidol and Protective effects of ginger on the testes of adults rats. (unindexed Abstract). The European Psychiatric Association, 29th European Congress of Psychiatry 2021. April 10-13, 2021. 15. Benjamin Adebisi (2021): Neuronal cells immunological response exacerbates Neurodegeneration. XXVI World Congress of Parkinson’s Disease and Related Disorders. 1-4 May, 2021. 16. Adebisi Benjamin: Antioxidants in foods: A Primary Potential remedy to Neurodegeneration (Abstract). The Movement Disorders online supplemengt and MDS Congress platform, e-poster presentation, and/oral presentation on the MDS Virtual Congress 2021 Platform. 17. Benjamin Temidayo Adebisi (2021): Microglia in Major Depressive Disorder and Suicidal Behaviour. 11th Conference of The International Society for Affective Disorders (Virtual). 3-4 November, 2021   SUMMARY OF RESEARCH AREAS Monosodium Glutamate (MSG) is the major constituent of condiments, commonly added to food, for improving taste; humans, generally, consume these condiments in their food to stimulate appetite. However, it has destructive effect on the neurons because it produces oxidative radicals which results in lipid peroxidation destroying the membrane of neurons. The glutamate also increases the intracytosolic calcium ions through increasing calcium ions permeability in the neurons; the cumulative effect of these is neurodegeneration. Neurodegeneration has been, in resent research, implicated in diseases such as Alzheimer’s disease, Huntington disease, Multiple sclerosis, and Parkinson’s disease. There is also evidence that spices and vegetables, consumed as food, contain a lot of antioxidants which mops up the oxidative radicals also called Reactive oxygen species (ROS), thereby ameliorating the extent of neurodegeneration caused by oxidative stress; the antioxidants also help in neuro- recovery and neuroprotection. I have been able to demonstrate an alteration in neurobehaviour, like anxiety, exploratory activities, learning and memory, in rats, that were administered with MSG, using neurobehavioural model test apparatus, like Morris Water Maze and Open Field Box; consequently, I have been able to describe, practically, the rationale of the biological basis of memory loss that is due to death of neurons in the hippocampus, the part of the brain responsible for spatial memory and learning. In my histology, I have also shown loss of neurons in animal subjects administered with Monosodium Glutamate and proved that the antioxidants present in plants, like ginger, could have ameliorative effects, hence attenuating the toxic effects, initiated by glutamate, due to generation of Reactive Oxygen Species. These discoveries has aroused my passion for the proposed used of plants derived antioxidants as a treated of neurodegenerative diseases. Parkinson’s disease is the most common neurodegenerative disease after Alzheimer’s disease; in the last 20 years, researches have been intense to see the cause and understand the biology of the etiopathogenesis of the disease. Although, genetics has being an area that has been looked into to understand the basis of the neurobiology; its main cause is still idiopathic. Over the last 3 years, I have researched repositories of publications in Parkinson’s disease, and related neurodegerative diseases alike, to explain the rationale of the linked protein, Alpha synuclein; that has been indicted in the pathology of the disease. I had made presentations in Africa, America and Europe, to explain the cause of death of neurons at the substantia nigra that have resulted in the loss of dopamine production due to the accumulation of alpha synuclein. I have, also, been able to link several genetic bases including Glucocerebrosidase gene. GBA, PARK 4, LRRK2 gene and SNCA, to the etiology of the neurodegenerative disease. I have five of my proposals passed the administrative phases of Michael J. Fox Foundation, MJFF, for Parkinson Research, explaining the biology of Alpha synuclein and its eventually resulting deaths of dopaminergic neuronal cells in the substantia nigra, pars compacta, a part of the Mid Brain and proposed therapeutic strategies in preventing and treating the disease. I have investigated the deteriorative effects of malnutrition on the nervous system, as a whole and see the corrective measures, using several nutrients, to reverse the effects of neurological symptoms posed by malnutrition on the neural system. Environmental toxicity of the nervous system also arouses my interest; as humans are exposed to toxic substances like lead, zinc, pesticides, and fertilizers, domestic and industrial wastes almost on daily basis. The effects of these toxins are debilitating on the brain, thereby affecting whole body system. The use of antipsychotics are also in wide range recently and little results have been achieved in bringing patients to premorbid states, I, therefore, have interest in seeing how genetic approaches could be used to detect causes of neuropsychiatric diseases and produce a better therapy for patients suffering from several psychiatric disease. I have research works on the toxic effects of tramadol, which is an opiod on the histoarchitecture of some viscerals in the body like the brain, heart, liver, kidney, stomach, lung and the testes and also the hematological parameters; this research was elucidated because of the growing and trending use of the drug among the populace, mainly youths. The outcome of the work showed clear and unequivocal damaging and devastating effects on these vital organs and consequently could result in overall systemic failure, loss of productivity and eventual shutdown, leading to death. The result of the research is aimed to advising drug abusers and government to enact strict policies on the distribution and consumption of opiates.   INVITATIONS AND CONFERENCE ATTENDANCE 1. 3rd International Neuroscience Conference/Advanced School/ Forum of the Institute of Neuroscience and Biomedical Research (INBR), Abuja, Nigeria. Theme: Neurodegeneration and Neuroregeneration 24th-30th July, 2010 2. 5th Annual SIDCAIN NCD Update Course, Guest Lecture and Scientific Conference. Osun State University, Osogbo. 2nd- 4th March, 2016 3. 16th Annual Scientific and General Meeting of Society of Experimental and Clinical Anatomists of Nigeria, Osogbo, Osun State. 26th- 29th April, 2017 4. The Brain Prize Outreach Program. Lundbeck Foundation in collaboration with The Danish Neuroscience Schools and Danish Society for Neuroscience. Hindsgavl Castle, Middelfart, Denmark. Theme: Rewarding Neuroscience 30th October- 1st November, 2017 5. Microbial Genomics and Surveillance Workshop. Osun State University, Osogbo. Nigeria. 2nd- 4th July, 2018 6. 17th Annual Molecular and Cellular Cognition Society Symposium and Poster Session. San Diego, California, United States of America. 1st – 2nd November, 2018. 7. The Brain Prize Outreach Program. Lundbeck Foundation in collaboration with The Danish Neuroscience Schools and Danish Society for Neuroscience. Hindsgavl Castle, Middelfart, Denmark. Theme: Dementia and Beyond 26th - 28th November, 2018 8. The First Young Researchers Conference on Genomics and Human Health in Africa. Khartoum, Sudan. 2nd – 7th December, 2018 9. 3rd Asian Conference on Science Technology & Medicine. Carlton Palace Hotel, Deira Dubai, UAE. 12th -14th February, 2019 10. 9th IMPRS NeuroCom Summer School, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstrasse. 1A, Leipzig, Germany. 16th -19th June 2019. 11. 19th World Psychiatry Association, World Congress of Psychiatry, Lisbon, Portugal. Theme: Psychiatry and Mental Health: Global Inspirations, locally Relevant Action. 21st – 24th August, 2019. 12. Synuclein Meeting: Where we are and where we need to go. Ofir, Porto, Portugal. 1st – 4th September, 2019. 13. 48th Meeting of The European Brain and Behavioural Society. Prague Congress Centre, Prague Czech Republic. 21st - 24th September, 2019. 14. International Congress of Parkinson’s disease and Movement Disorders, Nice, France. 22nd – 26th September, 2019. 15. XXV World Congress on Parkinson’s disease and Related Disorder. Prague, Czech Republic. 7th – 10th June, 2020. 16. 28th European Congress of Psychiatry. Madrid, Spain. The Shared Heritage of European Psychiatry. 4th -7th July, 2020. 17. Molecular and Cellular Cognition Society, MCCS 2020 Virtual Symposium. 21st- 22nd October, 2020. 18. The Brain Prize Meeting: Neurodevelopmental Disorders. Mechanism and Pathway to Treatment. 1-4 March, 2021 19. XXVI World Congress on Parkinson’s and Related Disorders. Maastricht. The Netherlands. 1st – 4th May, 2021. 20. 20th WPA World Congress of Psychiatry Virtual Congress, 10th -13th March, 2021. 21. 29TH European Congress of Psychiatry, Virtual Congress, 10 – 13 April, 2021. 22. The International Parkinson and Movement Disorder Society (MDS) Virtual Congresses September 17-22, 2021. 23. 11th Conference of The International Society for Affective Disorders (Virtual). 3-4 November, 2021 EDUCATIONAL TRAINING AND PARTICIPATION 1. ThermoFisher Scientific Virtual Genetic Solution Tour, 2020. 2. EPA 2021 Highlights: Insights into recent developments in Major Depressive Disorders and Relevance in Clinical Practice. 13 April, 2021. 3. Select Science Webinar: New Technologies Supporting Cell and Gene Therapy and Viral Vector Production. April 19, 2021. 4. 2021 Asian and Oceanian Section- Movement Disorder Society MDS-AOS Congress, AOPMC 2021. June 4-6, 2021 5. Scientific Programme by the European Accreditation Committee in Central Nervous System: “Managing Major Depressive Disorders, MDD, in Psychiatric emergencies”, Webinar on the Janssen NSME Forum Website, with Educational financial grant of Jassen Pharmaceutica NV, 24 June, 2021 6. MDS Networking and Engagement Series: Neurosurgery Special Interest Group, July 21, 2021 7. Virtual Aspen Course: A Comprehensive Review of Movement Disorders for the Clinical Practitioner. July 25-29 HONOUR AND AWARDS Academic Scholarship: The Federal Ministry of Education, Abuja, Nigeria. 2003 MDS Visiting Trainee Grant: International Parkinson and Movement Disorder Society, Milwaukee, Wisconsin, United States of America. 2019.   MEMBERSHIP OF PROFESSIONAL BODIES i. Member, Society for Experimental and Clinical Anatomists of Nigeria ii. Member, International Society for Neurochemistry (ISN) iii. Member, British Neuroscience Association (BNA) iv. Member, European Society of Neurochemistry (ESN) v. Member, European Brain and Behaviour Society (EBBS) vi. Member, Molecular and Cellular Cognition Society (MCCS) vii. Member, Forum for Neuroscience Society (FENS) viii. Member, Human Anatomy and Physiology Society (HAPS) ix. Member, Michael J. Fox foundation for Parkinson Research. (MJFF) x. Member, International Parkinson and Movement Disorder Society (MDS) xi. Member, Society for Neuroscience (SFN)   REFERENCES Dr. A.I.R Abioye Department of Anatomy University of Ilorin, Ilorin, Nigeria, +2348037251583, +2348055818413 Dr. F.M. Adeyemi Department of Microbiology, Osun State University, Nigeria. folasade,, +2348034940747 Dr. I.P.O. Oyeyipo Department of Physiology, Osun State University, Nigeria., +2348034146150.
no photo
Institut de pharmacologie moléculaire et cellulaire
AC Immune
Dr. Afroz’s research has focused on understanding molecular mechanisms of neurodegeneration and pathways for therapeutic interventions in various CNS indications. At AC Immune, Dr. Afroz serves as Team and project leader for TDP-43 antibody therapeutic program. Prior to joining AC Immune in 2017, Dr. Afroz was a post-doctoral scientist at the University of Zürich where he investigated the pathways that trigger aggregation of ALS/FTD-linked proteins, the mechanisms of neurotoxicity and the molecular basis of disease heterogeneity. Dr. Afroz obtained his master’s degree in Biotechnology at the Indian Institute of Technology in Mumbai. In 2013, he obtained his Ph.D. in Molecular Biology and Biophysics at ETH Zürich where he studied the role of sequence-specific protein-RNA interactions in RNA processing and metabolism.
no photo
University of Gothemburg
Department of psychiatry and neurochemistry
no photo
Medical Center Foltra
Scientific Direction
Neuropsychologist. Medical Center Foltra
Lund University
Clinical Memory Research Unit, Department of Clinical Sciences
Khazar Ahmadi is a postdoctoral fellow in Clinical Memory Research Unit at Lund University, Sweden. Her research interests revolve around the application of cutting-edge MRI techniques and computational models in clinical populations.
Imperial College London
Ageing Epidemiology Research Unit
I am an Assistant Professor (Lecturer) in the Epidemiology of Ageing at the Ageing Epidemiology Research Unit, Imperial college London. My research is focused on studying novel biological pathways leading to dementia by multi-modal analysis of genetic, fluid biomarker and neuroimaging data collected in large epidemiological studies. The aim is to reveal unidentified dementia subtypes and identification of early detection or therapeutic targets. My other line of research which I started as postdoctoral researcher at the UCL Department of Epidemiology and Public Health involves public health Markov modelling to forecast the future burden of dementia and disability at population level and estimating the impact of public health interventions on prevalence of these conditions. I hold an MD degree in Medicine from Tehran University and obtained MPhil and PhD degrees in Epidemiology from the University of Cambridge on a Gates Cambridge Scholarship and an honorary Krishnan-Ang Scholarship from Trinity College.